Share on facebook Share on Twitter Share on Google Plus Share This

Hematology/Oncology

Pediatric Cancer Care

An expert team that cares for and about your child

If your child has been diagnosed with cancer or a blood disorder, you are probably anxious and worried about what will happen next. At Floating Hospital for Children at Tufts Medical Center in Boston, you’ll know the peace of mind that comes as a result of an exceptional team of pediatric oncologists and hematologists who treat these complex diseases.

The Division of Pediatric Hematology/Oncology provides a level of intimacy, agility and close collaboration that you simply will not find at larger hospitals. Our nationally-renowned team has strong expertise in treating all types of pediatric cancers and blood disorders, including:

Our FACT accredited bone marrow transplant program offers bone marrow transplant for patients with pediatric cancers, bone marrow failure syndromes, sickle cell disease, thalassemia and immunodeficiencies.

Why choose us

Our strength is in providing comprehensive pediatric hematology and oncology services by integrating specialists in all aspects of cancer and hematology care. As seasoned medical and nursing staff, researchers, social workers and child life specialists, we form a close-knit team that works to achieve the best possible outcomes for your child.

At Floating Hospital, we know you don’t have to be big to be strong. We believe in the strength of our patients — it motivates us to deliver the highest level of care and provide support for their families when they need it most.

Clinical research is also an important part of our care. We are active members of the Children’s Oncology Group and the Neuroblastoma Medulloblastoma Translational Research Consortium. We also offer enrollment in industry-sponsored clinical trials. Fifty percent of our pediatric cancer patients enroll in a clinical trial, and 25% enroll in more than one trial.

We offer the newest and most effective treatments currently available along with a track record of excellent outcomes, including survival rates for acute lymphoblastic leukemia that are better than national averages. 1

References 

1Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2013, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER web site, April 2016.

News


Call Us
617-636-5535